Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.
Carbapenem-resistant
Extensive-drug-resistant
Meropenem
Or amikacin
Propranolol
Tigecycline
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
22 07 2023
22 07 2023
Historique:
received:
03
03
2023
accepted:
04
07
2023
medline:
24
7
2023
pubmed:
23
7
2023
entrez:
22
7
2023
Statut:
epublish
Résumé
Infection with extensive-drug-resistant (XDR) carbapenem-resistant (CR) Gram-negative bacteria (GNB) are viewed as a serious threat to human health because of the limited therapeutic options. This imposes the urgent need to find agents that could be used as adjuvants or combined with carbapenems to enhance or restore the susceptibility of XDR CR- GNB. Therefore, this study aimed to examine the effect of propranolol (PR) in combination with Meropenem (MEM) on the susceptibility profile of XDR CR-GNB recovered from severely infected patients as well as to evaluate combining MEM with either tigecycline (TGC) or amikacin (AK). A total of 59 non-duplicate CR- GNB were investigated for carbapenemase production by the major phenotypic methods. Molecular identification of five major carbapenemase-coding genes was carried out using polymerase chain reactions (PCR). Antimicrobial susceptibility tests were carried out using standard methods. Phenotypic and genotypic relatedness was carried out using the heatmap and ERIC PCR analysis. PR, 0.5 -1 mg/mL against the resulting non-clonal XDR CR-GNB pathogens were evaluated by calculating the MIC decrease factor (MDF). A combination of MEM with either AK or TGC was performed using the checkerboard assay. A total of 21 (35.6%) and 38 (64.4%) CR-GNB isolates were identified as enterobacterial isolates (including 16 (27.1%) Klebsiella Pneumoniae and 5 (8.5%) Escherichia coli) and non-fermentative bacilli (including, 23 (39%), Acinetobacter baumannii, and 15 (25.4%) Pseudomonas aeruginosa). The heatmap and ERIC PCR analysis resulted in non-clonal 28 XDR CR isolates. PR, at a concentration of 0.5 mg /ml, decreased MICs values of the tested XDR CR isolates (28; 100%) and restored susceptibility of only 4 (14.3%) isolates. However, PR (1 mg/mL) when combined with MEM has completely (28; 100%) restored the susceptibility of the tested XDR CR- GNB to MEM. The MEM + AK and MEM + TGC combination showed mostly additive effects (92.8% and 71.4%, respectively). PR at a concentration of 1 mg/mL restored the susceptibility of XDR CR- GNB to MEM which is considered a promising result that should be clinically investigated to reveal its suitability for clinical use in patients suffering from these life-threatening pathogens.
Sections du résumé
BACKGROUND
Infection with extensive-drug-resistant (XDR) carbapenem-resistant (CR) Gram-negative bacteria (GNB) are viewed as a serious threat to human health because of the limited therapeutic options. This imposes the urgent need to find agents that could be used as adjuvants or combined with carbapenems to enhance or restore the susceptibility of XDR CR- GNB. Therefore, this study aimed to examine the effect of propranolol (PR) in combination with Meropenem (MEM) on the susceptibility profile of XDR CR-GNB recovered from severely infected patients as well as to evaluate combining MEM with either tigecycline (TGC) or amikacin (AK).
METHODS
A total of 59 non-duplicate CR- GNB were investigated for carbapenemase production by the major phenotypic methods. Molecular identification of five major carbapenemase-coding genes was carried out using polymerase chain reactions (PCR). Antimicrobial susceptibility tests were carried out using standard methods. Phenotypic and genotypic relatedness was carried out using the heatmap and ERIC PCR analysis. PR, 0.5 -1 mg/mL against the resulting non-clonal XDR CR-GNB pathogens were evaluated by calculating the MIC decrease factor (MDF). A combination of MEM with either AK or TGC was performed using the checkerboard assay.
RESULTS
A total of 21 (35.6%) and 38 (64.4%) CR-GNB isolates were identified as enterobacterial isolates (including 16 (27.1%) Klebsiella Pneumoniae and 5 (8.5%) Escherichia coli) and non-fermentative bacilli (including, 23 (39%), Acinetobacter baumannii, and 15 (25.4%) Pseudomonas aeruginosa). The heatmap and ERIC PCR analysis resulted in non-clonal 28 XDR CR isolates. PR, at a concentration of 0.5 mg /ml, decreased MICs values of the tested XDR CR isolates (28; 100%) and restored susceptibility of only 4 (14.3%) isolates. However, PR (1 mg/mL) when combined with MEM has completely (28; 100%) restored the susceptibility of the tested XDR CR- GNB to MEM. The MEM + AK and MEM + TGC combination showed mostly additive effects (92.8% and 71.4%, respectively).
CONCLUSION
PR at a concentration of 1 mg/mL restored the susceptibility of XDR CR- GNB to MEM which is considered a promising result that should be clinically investigated to reveal its suitability for clinical use in patients suffering from these life-threatening pathogens.
Identifiants
pubmed: 37481513
doi: 10.1186/s12866-023-02934-6
pii: 10.1186/s12866-023-02934-6
pmc: PMC10362616
doi:
Substances chimiques
Meropenem
FV9J3JU8B1
Propranolol
9Y8NXQ24VQ
Amikacin
84319SGC3C
Tigecycline
70JE2N95KR
Carbapenems
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
195Informations de copyright
© 2023. The Author(s).
Références
Antibiotics (Basel). 2021 Apr 30;10(5):
pubmed: 33946253
Infect Chemother. 2014 Sep;46(3):149-64
pubmed: 25298904
Mol Biol Rep. 2019 Feb;46(1):609-616
pubmed: 30603949
Microb Drug Resist. 2017 Jun;23(4):437-446
pubmed: 27564414
PLoS One. 2018 Jan 3;13(1):e0189950
pubmed: 29298353
Diagn Microbiol Infect Dis. 2020 Jan;96(1):114912
pubmed: 31704067
J Control Release. 2004 Mar 24;95(3):447-53
pubmed: 15023456
Int J Antimicrob Agents. 2011 Mar;37(3):244-7
pubmed: 21236643
PLoS One. 2019 Oct 29;14(10):e0224107
pubmed: 31661500
Clin Microbiol Infect. 2003 Jan;9(1):1-14
pubmed: 12691538
Ann Transl Med. 2019 Oct;7(20):566
pubmed: 31807547
Infect Disord Drug Targets. 2020;20(2):182-197
pubmed: 30474540
J Med Microbiol. 2023 Feb;72(2):
pubmed: 36762530
J Dermatolog Treat. 2018 May;29(3):310-313
pubmed: 28748731
J Appl Microbiol. 2013 May;114(5):1294-9
pubmed: 23414263
J Clin Microbiol. 2012 Dec;50(12):3877-80
pubmed: 22993175
Euro Surveill. 2017 Feb 9;22(6):
pubmed: 28205502
Curr Med Chem. 2019;26(28):5363-5388
pubmed: 29984648
Microb Drug Resist. 2019 May;25(4):480-488
pubmed: 30394846
Sci Rep. 2022 May 9;12(1):7541
pubmed: 35534512
Infect Drug Resist. 2018 Aug 22;11:1261-1269
pubmed: 30197524
J Clin Microbiol. 2005 Jan;43(1):140-3
pubmed: 15634962
Antimicrob Agents Chemother. 2010 Nov;54(11):4678-83
pubmed: 20713678
Dermatol Ther. 2017 May;30(3):
pubmed: 27891741
Biology (Basel). 2021 Sep 09;10(9):
pubmed: 34571766
Infect Drug Resist. 2019 Nov 15;12:3567-3573
pubmed: 31814745
Scars Burn Heal. 2019 Feb 19;5:2059513119831369
pubmed: 30815282
3 Biotech. 2022 Jan;12(1):30
pubmed: 35070620
Antibiotics (Basel). 2020 Dec 09;9(12):
pubmed: 33317111
Front Cell Infect Microbiol. 2019 Jun 11;9:193
pubmed: 31245302
J Clin Microbiol. 2013 Sep;51(9):2986-90
pubmed: 23843486
J Antimicrob Chemother. 2018 Apr 1;73(4):909-915
pubmed: 29365094
Antibiotics (Basel). 2021 Aug 23;10(8):
pubmed: 34439073
Int J Antimicrob Agents. 2022 Oct;60(4):106668
pubmed: 36038097
J Clin Microbiol. 2013 Dec;51(12):4281-3
pubmed: 24108615
Clin Microbiol Infect. 2012 May;18(5):432-8
pubmed: 22507110
Nucleic Acids Res. 1991 Dec 25;19(24):6823-31
pubmed: 1762913
Medicine (Baltimore). 2015 Jul;94(27):e1097
pubmed: 26166098
Transl Res. 2020 Jun;220:14-32
pubmed: 32201344
Antibiotics (Basel). 2021 Oct 29;10(11):
pubmed: 34827263
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
PLoS One. 2019 Sep 12;14(9):e0222168
pubmed: 31513633
PLoS One. 2016 Jun 22;11(6):e0156509
pubmed: 27331395
J Clin Microbiol. 1990 Sep;28(9):1903-5
pubmed: 2229371
Clin Microbiol Infect. 2016 Mar;22 Suppl 1:S15-25
pubmed: 26627340
Int J Antimicrob Agents. 2000 Apr;14(3):249-51
pubmed: 10773497
Crit Care Nurse. 2008 Feb;28(1):15-25; quiz 26
pubmed: 18238934
Infect Drug Resist. 2020 Sep 11;13:3113-3124
pubmed: 32982326
J Clin Pathol. 1998 Apr;51(4):316-23
pubmed: 9659247
Curr Opin Infect Dis. 2014 Dec;27(6):479-83
pubmed: 25259809
Front Cell Infect Microbiol. 2022 Mar 15;12:823684
pubmed: 35372099
PLoS One. 2020 Aug 26;15(8):e0238195
pubmed: 32845920
Infection. 2019 Jun;47(3):497-500
pubmed: 30734249
Expert Rev Anti Infect Ther. 2016 Aug;14(8):747-63
pubmed: 27400643
J Clin Microbiol. 2002 Oct;40(10):3798-801
pubmed: 12354884
Int J Antimicrob Agents. 2021 May;57(5):106344
pubmed: 33857539
BMC Res Notes. 2020 Aug 10;13(1):380
pubmed: 32778154
Indian J Med Res. 2021 Mar;154(3):520-526
pubmed: 35345078
BMC Microbiol. 2022 Oct 14;22(1):248
pubmed: 36229768
Diagn Microbiol Infect Dis. 2019 Aug;94(4):413-425
pubmed: 30905487
Future Sci OA. 2020 Jan 27;6(3):FSO438
pubmed: 32140243